I still think CB 03 01 is one of the nearest and most promising things because we know it will work. Propecia did the dirty work already we know what an AA can do and since this would be the first topical I think the sides will be minimal compared to propecia. I just hope its powerful and the vehicle gets the job done.
Of course, we have to wait and see. There are no sure things here and its going to be a long wait.
CB-03-01 - new antiandrogenic
Collapse
X
-
There is no way they are going to tell people what the vehicle and recipe are. they are trying to sell it. we're gonna have to wait. we also don't even know if this stuff works or how well it will work, people on here hype shit up so much it's ridiculous. androgens are only part of the problem, as has been proved by finasteride. this might be a nice treatment, but a POC will take a year, phase one another, phase two another, phase three another etc. it takes 8 years to go through trials, maybe take two off if we're lucky because it's proven safe for acne. and then still I'm sure it will have side effects if it does work. everything has side effects, which is why stem cell treatments are exciting, because they di not use foreign drugs.Leave a comment:
-
-
Another small update from cosmo:
CB-03-01:
• Only topical antiandrogen for treatment of acne and alopecia in
development
• Outlicensed to Medicis/Valeant with $ 25m signing fee plus milestones
and low double digit royalties
• Phase II completed in acne:
• no major adverse event ocurred
• data report available shortly
• $ 20m milestone is due upon successful EOP II meeting with
FDA scheduled for September
• POC in alopecia to start H2 2014: $ 10m milestone at completion
(6 months treatment; overall one year trial)
Once Phase 2 starts - is this when we will be able to find out what the vehicle is?Leave a comment:
-
Another small update from cosmo:
CB-03-01:
• Only topical antiandrogen for treatment of acne and alopecia in
development
• Outlicensed to Medicis/Valeant with $ 25m signing fee plus milestones
and low double digit royalties
• Phase II completed in acne:
• no major adverse event ocurred
• data report available shortly
• $ 20m milestone is due upon successful EOP II meeting with
FDA scheduled for September
• POC in alopecia to start H2 2014: $ 10m milestone at completion
(6 months treatment; overall one year trial)
Usually that means not having to go through a long phase II process, they could do Phase II within a year(arent they in Pre-clinical for the MPB treatment?)
So sounds like BIM and CB will be our near future options as of now.Leave a comment:
-
Another small update from cosmo:
CB-03-01:
• Only topical antiandrogen for treatment of acne and alopecia in
development
• Outlicensed to Medicis/Valeant with $ 25m signing fee plus milestones
and low double digit royalties
• Phase II completed in acne:
• no major adverse event ocurred
• data report available shortly
• $ 20m milestone is due upon successful EOP II meeting with
FDA scheduled for September
• POC in alopecia to start H2 2014: $ 10m milestone at completion
(6 months treatment; overall one year trial)
Nice man, one year phase 2 trial. They could be finished with Phase 2 alopecia trial by end of next year. Then if they enter phase 3 thats it.Leave a comment:
-
Ingredient needs to sink underneath the skin. I can't see the cream working at all.Leave a comment:
-
Another small update from cosmo:
CB-03-01:
• Only topical antiandrogen for treatment of acne and alopecia in
development
• Outlicensed to Medicis/Valeant with $ 25m signing fee plus milestones
and low double digit royalties
• Phase II completed in acne:
• no major adverse event ocurred
• data report available shortly
• $ 20m milestone is due upon successful EOP II meeting with
FDA scheduled for September
• POC in alopecia to start H2 2014: $ 10m milestone at completion
(6 months treatment; overall one year trial)Leave a comment:
-
-
Could this be the the compound of CB cream:
excipients of CB-03-01 1% cream (cetyl alcohol, glyceryl
monostearate, liquid paraffin, propylene glycol, tocopherol,
sodium edetate, polysorbate 80, water).
page 2 Study design and treatmentLeave a comment:
-
Could this be the the compound of CB cream:
excipients of CB-03-01 1% cream (cetyl alcohol, glyceryl
monostearate, liquid paraffin, propylene glycol, tocopherol,
sodium edetate, polysorbate 80, water).
page 2 Study design and treatmentLeave a comment:
-
Good news:
ClinicalTrials.gov Identifier: NCT01631474
Study Title: A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
First Received: June 27, 2012
Last Updated: May 29, 2014
Source:
Looks like Phase II trials are done.
I can't find the Cosmo's presentation of the recent conference in NY.Leave a comment:
-
shouldn't we try to contact cosmo and ask if an early release in asia is an option?
i mean, 2 phases are really enough to see safety and efficiency, so why not throw it on the market already and make some cash? at least they could sell it off-label or under a different name if they are afraid of some marketing complications or whatever.
would be worth a try, there's nothing to lose... is someone already in contact with them by email?Leave a comment:
-
I contacted replicel about early release in asia due to new rules by japan. bottom line is replicel expects to release their product early in asia. I cant think of a reason why cb won't be there sooner, not to mention others. evry body will be cashing in there. I really hope the west catches up. pretty sure europe will, but the US is a whole different story.if it becomes profitable in japan, big companies here will be influencing the FDA to do the same.Leave a comment:
-
Leave a comment: